SlideShare ist ein Scribd-Unternehmen logo
1 von 25
Downloaden Sie, um offline zu lesen
BCN Biosciences Team - Andrew Norris (PI), Mai Brooks (IE), Sudip Chakrabortty (CL) Validating Business Model for – Drug that increases anti-cancer effect of radiation in lung cancer (and/or reduces normal tissue damage by at least 40% compared to standard of care) 
Team 07 
I-Corps @ NIH – Dec 09, 2014 
Interviews total= 101 
Avg/wk = 10
What we thought going into of ICorps 
2 
1 indication – Radiation Mitigation 
Radiation Oncologists the main customer segment 
Some MOA data is important 
Phase1 Clinical Trials data required to license out the molecule 
We need to raise $5M+ to take the technology forward and it would take 6 years
The ICorps Journey – Customer Discovery 
3
Week 1 Canvas 
4
Right Side Canvas Week 1 
Indication 
Customer segment 
Value Proposition 
Minimal Viable Product 
Investment Readiness 
Normal Tissue Protection from Radiation 
Radiation & 
Clinical Oncologists 
Protects lung / normal tissue from radiation 
Lung fibrosis and pneumonitis 
•8 
5
Left Side Canvas Week 3 
Value Prop 
Key Activities 
Key Partners 
Minimal Viable Product 
Normal tissue protection 
Show tissue protection in various animal models. 
Limit Lung fibrosis and pneumonitis 
Academic 
•Animal models showing normal tissue protection. 
6
What we did - Archetypes of Customer & Partners 
Doctors 
Pharma Biz Dev 
Pharma Prod Dev / Science 
Development Partners 
Archetype 
Pulmonologists 
-patients with post radiation fibrosis 
-patients with IPF 
Skin Doctors 
-Dermatologists 
-Plastic Surgeons 
Big Pharma/Biotech 
-Pitched hundreds of times each year 
-Looking for $1B market molecules 
-Disease modifying 
Medium Pharma/Biotech 
-Actively engaged in pre- clinical scouting 
-Interested in supportive care also 
Big & Medium Pharma/ Biotech 
-Conducts pre-clinical MOA studies 
-Conducts Efficacy & Safety studies 
-Designs in-human clinical trials and regulatory path 
-Primary Science/ Regulatory/manuf decision influencers 
CROs 
-Radiation CROs 
-PK, Tox & Efficacy CROs 
-Drug Formulations 
-Drug manufacturing 
Govt. Agencies 
-Development partner 
-Free resources 
Disease Foundations 
-Basic Research support mandate 
-Orphan Indications 
Interviewees 
26 
34 
18 
22 
7
8 
The BCN Strategy evolution at ICorps@NIH 
Week 1 
Week 6 
Week 10 
Radiation Mitigator & Tumor Sensitizer 
Prevents Radiation Induced Lung Fibrosis 
1 
8
9 
The BCN Strategy evolution at ICorps@NIH 
Week 1 
Week 6 
Week 10 
Radiation Tumor Sensitizer 
Prevents Radiation Induced Lung Fibrosis 
Fibrosis 
Possible MOA – Stem Cell 
Big Market size for fibrosis – unmet need 
1 
9
10 
The BCN Strategy evolution at ICorps@NIH 
Week 1 
Week 6 
Week 10 
Radiation Mitigator & Tumor Sensitizer 
Prevents Radiation Induced Lung Fibrosis 
Fibrosis 
Possible MOA – Stem Cell 
Lung Fibrosis (IPF*) 
Skin Fibrosis 
(Anti aging) 
Other Fibrosis types 
Big Market size for fibrosis – unmet need 
1 
2 
3 
* Idiopathic Pulmonary Fibrosis 
10
Week 7 Canvas 
6 Hypothesis Validated, >15 invalidated 
11
Week 10 Canvas 
16 Hypothesis Validated, 10+ validation still in progress 
12
Right Side Canvas Week 10 
Value Prop 
Customer segment 
Value Proposition 
Minimal Viable Product 
Investment Readiness 
Tumor Sensitizer 
Radiation Oncologists 
In-License/BD 
Increase survival >3 months vs. SOC 
•Reduces tumor burden vs Radiation. 
•MOA 
•5-6 
IPF 
Pulmonologists 
In-License/BD 
Reduce pulmonary fibrosis > SOC 
•2 more animal models for IPF 
•MOA 
•2-3 
Anti-aging 
Dermatologists 
Reduces age related markers 
•Mini pig skin injury model. 
•Human test- reduce collagen over 6 months 
•2 
13
Market Size – TAM, SAM, Target 
Yearly Cancer Incidences 
= 5.1M 
Lung = 630K 
Radiation Therapy = 410K 
Mortality = 160K 
Radiation 
Complications 
= 64K 
TAM = $6B 
SAM = $2B 
Target Market = $1B 
Indication – Radiation Sensitizer for Lung Cancer Tumors 
14
Left Side Canvas Week 10 
Value Prop 
Key Activities 
Key Partners 
Minimal Viable Product 
Tumor Sensitizer 
MVP = 
•MOA, 
•Animal (reduces tumor burden vs radiation alone). 
• (TPP) Tumor sensitizer that increases life by at least 3 months in conjunction with SOC. 
Cleveland Bio 
UCLA, 
•Sensitizes tumor tissue to radiation vs radiation alone. 
•Lung fibrosis and pneumonitis 
IPF 
MVP = MOA!!, two other models that show better efficacy than standard of care, work with ……*(Companies Names) 
Lovelace 
•MOA 
•2 more animal models for IPF 
Anti-aging 
MVP (strong prelim data showing reduction in collagen production in mouse model and human skin (over 6 months). 
CitoxLab North America. 
•Mini pig skin injury model. 
•Human test-reduce collagen over 6 months 
15
Companies & KOL 
Possible 
Customers 
Competi- tors 
KOL 
Dr. Andre Gudkov 
Dr. Robert Figlin 
Dr. Luca Richeldi 
Dr. Talmadge King 
Dr. Richard Fitzpatrick 
Radiation sensitizer, target companies that sell lung cancer drugs 
IPF, target companies that sell drugs for lung disease 
Anti-aging cream, target companies that sell skin products 
1 
2 
3 
16
Customer Relationship-Commitment Diagram 
17 
BCN 
Bio 
BCN Biz Dev Sci Ad Board 
Months 0 1 6 12 18 
Network 
Scientific meetings & trade shows 
Grants, pubs 
License, venture deal 
Design & do clinical trial 
GET 
GROW 
Pharma licensing Decision Makers 
Pharma Venture Venture Capital 
Doctors 
Customers 
KEEP
Partners – Preclinical /Phase 1 Clinical 
Partner Type 
Partner Name 
Why Partner & What Risk 
Why BCN & Costs 
Incentives 
CML & AAI Pharma – Formulation & Drug product 
- Industry standard & GMP 
- No in-house facilities @ BCN 
Risk - Partner Project Management 
- CRO business model 
- New areas to show expertise & publish (radiation & IPF) 
Costs ~ $600K (pre-clin) 
- Revenue Model 
- New Business possibilities 
CiToxLAB/SNBL – Radiation & Cancer Efficacy & Safety 
Lovelace – Pulmonary Indication Efficacy & Safety 
- Industry Standard & GLP 
- No in-house facilities 
Risk – Partner Project Management & IP share on any new animal model 
- CRO business model 
- New areas to show expertise & publish (radiation & IPF 
- Potential shared IP on animal model 
Costs ~ $1.1M (pre-clin) 
- Revenue Model - Potential IP 
- New Business possibilities 
UCLA 
Expertise in Radiation Sensitizer Animal Model & related MOA 
- BCN team has significant Pharma expertise in the relevant fields 
- Not many pharma or biotech working on this filed 
Unique ability to bring Academia, Govt. & Industry together 
Costs ~ $500K (sponsored research) 
- In the Academic institutions best interest to help commercialize IP originally funded by grants 
- Publications 
- Extra funding in form of sponsored Research 
Albert Einstein College of Medicine 
Expertise in Head & Neck animal model (Mucositis) 
University of Maryland (probable) 
Expertise in Pulmonary Fibrosis Animal model & related MOA 
Risk – Potential IP issues 
CRO 
Academia 
18
Partners – Preclinical /Phase 1 Clinical 
Partner Type 
Partner Name 
Why Partner & What Risk 
Why BCN & Costs 
Incentives 
CML & AAI Pharma – Formulation & Drug product 
- Industry standard & GMP 
- No in-house facilities @ BCN 
Risk - Partner Project Management 
- CRO business model 
- New areas to show expertise & publish (radiation & IPF) 
Costs ~ $600K (pre-clin) 
- Revenue Model 
- New Business possibilities 
CiToxLAB/SNBL – Radiation & Cancer Efficacy & Safety 
Lovelace – Pulmonary Indication Efficacy & Safety 
- Industry Standard & GLP 
- No in-house facilities 
Risk – Partner Project Management & IP share on any new animal model 
- CRO business model 
- New areas to show expertise & publish (radiation & IPF 
- Potential shared IP on animal model 
Costs ~ $1.1M (pre-clin) 
- Revenue Model - Potential IP 
- New Business possibilities 
UCLA 
Expertise in Radiation Sensitizer Animal Model & related MOA 
- BCN team has significant Pharma expertise in the relevant fields 
- Not many pharma or biotech working on this filed 
Unique ability to bring Academia, Govt. & Industry together 
Costs ~ $500K (sponsored research) 
- In the Academic institutions best interest to help commercialize IP originally funded by grants 
- Publications 
- Extra funding in form of sponsored Research 
Albert Einstein College of Medicine 
Expertise in Head & Neck animal model (Mucositis) 
University of Maryland (probable) 
Expertise in Pulmonary Fibrosis Animal model & related MOA 
Risk – Potential IP issues 
CRO 
Academia 
19 
There are Risks in Partnerships also - we need to be aware
Partners – Preclinical /Phase 1 Clinical 
Partner Type 
Partner Name 
Why Partner & What Risk 
Why BCN & Costs 
Incentives 
NCI SBIR & Next program 
- For Radiation & Cancer 
NHLBI SBIR and other program – For IPF indication 
- Phase 1 & Phase 2 funding 
- Access to World Class facilities for free 
Risk - Risk of not getting selected, so need plan B 
- One of the promising your SB biotech working on other indications for Radiation Mitigators 
-Govt. mandate 
Costs – No costs to BCN 
- Stimulating economy through fundamental research 
NIAID & BARDA 
- NIAID funding covers most IND enabling studies 
- BARDA Contracts can be utilized for Clinical trials using Animal Rule 
Risk – Risk of not getting selected, Tech Readiness Level 5 required 
- BARDA especially looking for molecules with other in-human indications 
Costs – No costs to BCN 
- Public Safety 
-Maximum return on tax payer dollars 
Pharma & Biotech interested in Radiation Sensitizer & Cancer indications 
-Perform MOA studies pre- IND (research) 
-Scale up GMP formulation & drug product pre-IND 
-Experts in IP protection 
-Expertise in Clinical Trials & Regulatory 
-Sales & Marketing Channels 
-License out within 3 years 
Risk – They might kill the project 
- BCN team has pre- eminent Prod Dev expertise in the relevant fields 
- Orphan Indication (IPF) 
-Smart use of partnerships 
Costs – Giving up control and big future Revenue Potential 
- Potential Radiation Sensitizer & Head & Neck cancer indication market big 
- Picking up a multi-indication molecule for cheap 
Pharma & Biotech interested in Pulmonary Fibrosis 
Govt. 
Agencies 
Pharma & Biotech 
20
Partners – Preclinical /Phase 1 Clinical 
Partner Type 
Partner Name 
Why Partner & What Risk 
Why BCN & Costs 
Incentives 
NCI SBIR & Next program 
- For Radiation & Cancer 
NHLBI SBIR and other program – For IPF indication 
- Phase 1 & Phase 2 funding 
- Access to World Class facilities for free 
Risk - Risk of not getting selected, so need plan B 
- One of the promising your SB biotech working on other indications for Radiation Mitigators 
-Govt. mandate 
Costs – No costs to BCN 
- Stimulating economy through fundamental research 
NIAID & BARDA 
- NIAID funding covers most IND enabling studies 
- BARDA Contracts can be utilized for Clinical trials using Animal Rule 
Risk – Risk of not getting selected, Tech Readiness Level 5 required 
- BARDA especially looking for molecules with other in-human indications 
Costs – No costs to BCN 
- Public Safety 
-Maximum return on tax payer dollars 
Pharma & Biotech interested in Radiation Sensitizer & Cancer indications 
-Perform MOA studies pre- IND (research) 
-Scale up GMP formulation & drug product pre-IND 
-Experts in IP protection 
-Expertise in Clinical Trials & Regulatory 
-Sales & Marketing Channels 
-License out within 3 years 
Risk – They might kill the project 
- BCN team has pre- eminent Prod Dev expertise in the relevant fields 
- Orphan Indication (IPF) 
-Smart use of partnerships 
Costs – Giving up control and big future Revenue Potential 
- Potential Radiation Sensitizer & Head & Neck cancer indication market big 
- Picking up a multi-indication molecule for cheap 
Pharma & Biotech interested in Pulmonary Fibrosis 
Govt. 
Agencies 
Pharma & Biotech 
21 
Partnership is a 2 way street – Partners expect specific things from BCN too
What we thought going into of ICorps 
22 
1 indication – Radiation Mitigation 
Radiation Oncologists the main customer segment 
Some MOA data is important 
Phase1 Clinical Trials data required to license out the molecule 
We need to raise $5M+ to take the technology forward and it would take 6 years
So what did we really learn in 10 weeks at ICorps 
23 
1 indication – Radiation Mitigation 
Radiation Oncologists the main customer segment 
Some MOA data is important 
Phase1 Clinical Trials data required to license out the molecule 
We need to raise $5M+ to take the technology forward and it would take 6 years 
3 possible indications – & Tumor Sensitization; IPF, Skin 
Pharma company in-licensing Directors most important customer segment 
MOA data is required for 2 of the 3 indications 
Its possible to license out or partner at a pre-IND stage 
We can do this in <$2M and in <3 years
BCN Biosciences – Next Steps 
•With respect to submitting an SBIR/STTR Phase II application, we will write on our primary indication of radiation sensitizer/protector in lung cancer. 
•The feasibility data generated in the Phase I grant provide the appropriate technical foundation for a Phase II application, AND we are largely targeting the customer segments that we had originally anticipated 
•TRL level 6 
24
Timeline 
Stage 
Activities 
Partners 
Key Markers 
Timeline 
Pre-Clinical 
Phase 1 
Phase 2 
Phase 3 
IND Data Package 
Pharma Data Package 
Safety 
Initial MOA 
Efficacy 
Academia 
CRO 
Govt 
CRO 
BCN Biosciences 
Pharma Partner/s 
$ 
$ 
$ 
$ 
$ 
$ 
$ 
$ 
$ 
$ 
$ 
$ 
$ 
$ 
D 
F 
A 
$ 
B 
C 
G 
6 months 
6 months 
18 months 
1 year 
2 years 
4 years 
10 years 
A 
B 
C 
D 
E 
F 
C 
License Molecule from Academia 
Sponsored Research @ Academia 
Govt. Grant/Cooperative Agmt/Contract 
Partnership Agreement with Pharma 
License molecule out to Pharma 
E.g. Milestone Payments to BCN 
Royalty Payments to BCN 
25 
IND 
E 
F 
FDA 
Approval 
Definitive MOA Studies 
Clinical Trials 
Animal Model Dev 
CMC 
Sales & Marketing

Weitere ähnliche Inhalte

Was ist angesagt?

Metabical case study
Metabical case studyMetabical case study
Metabical case studyKakoli Laha
 
Competitor Analysis Templates Our Competitors Losing Market Gaining Market
Competitor Analysis Templates Our Competitors Losing Market Gaining Market Competitor Analysis Templates Our Competitors Losing Market Gaining Market
Competitor Analysis Templates Our Competitors Losing Market Gaining Market SlideTeam
 
Market Opportunity Navigator, Lesson 1: Overview
Market Opportunity Navigator, Lesson 1: OverviewMarket Opportunity Navigator, Lesson 1: Overview
Market Opportunity Navigator, Lesson 1: OverviewWhere to Play
 
Costco Powerpoint Presentation
Costco Powerpoint PresentationCostco Powerpoint Presentation
Costco Powerpoint Presentationguest754917
 
UCSF Life Sciences Week 1 diagnostics
UCSF Life Sciences Week 1 diagnosticsUCSF Life Sciences Week 1 diagnostics
UCSF Life Sciences Week 1 diagnosticsStanford University
 
0103 b marketing management case study report xerox 1 (1)
0103 b marketing management case study report xerox 1 (1)0103 b marketing management case study report xerox 1 (1)
0103 b marketing management case study report xerox 1 (1)Marcelo Augusto A. Cosgayon
 
Medical representative day
Medical representative  dayMedical representative  day
Medical representative dayNabil Awan
 
UCSF Life Sciences Week 2 devices
UCSF Life Sciences Week 2 devicesUCSF Life Sciences Week 2 devices
UCSF Life Sciences Week 2 devicesStanford University
 
The Invincible Company
The Invincible CompanyThe Invincible Company
The Invincible CompanyYves Pigneur
 
Valuations: What is happening and does it matter?
Valuations: What is happening and does it matter?Valuations: What is happening and does it matter?
Valuations: What is happening and does it matter?taliagold
 
Investment Thesis Fundamentals (April 2016)
Investment Thesis Fundamentals (April 2016)Investment Thesis Fundamentals (April 2016)
Investment Thesis Fundamentals (April 2016)Dave McClure
 
Introducing Go To Market Strategy for B2B Startups
Introducing Go To Market Strategy for B2B StartupsIntroducing Go To Market Strategy for B2B Startups
Introducing Go To Market Strategy for B2B StartupsHugh MASON
 
Go to Market Strategy - Hemopure
Go to Market Strategy - HemopureGo to Market Strategy - Hemopure
Go to Market Strategy - HemopureChris Serio
 
Indian Pharmaceutical Industry
Indian Pharmaceutical IndustryIndian Pharmaceutical Industry
Indian Pharmaceutical IndustrySiddhartha Roy
 

Was ist angesagt? (20)

Merck & CO
Merck & COMerck & CO
Merck & CO
 
Metabical case study
Metabical case studyMetabical case study
Metabical case study
 
Competitor Analysis Templates Our Competitors Losing Market Gaining Market
Competitor Analysis Templates Our Competitors Losing Market Gaining Market Competitor Analysis Templates Our Competitors Losing Market Gaining Market
Competitor Analysis Templates Our Competitors Losing Market Gaining Market
 
Metabical
MetabicalMetabical
Metabical
 
Genicell Pitch Deck
Genicell Pitch DeckGenicell Pitch Deck
Genicell Pitch Deck
 
Market Opportunity Navigator, Lesson 1: Overview
Market Opportunity Navigator, Lesson 1: OverviewMarket Opportunity Navigator, Lesson 1: Overview
Market Opportunity Navigator, Lesson 1: Overview
 
Olay.pdf
Olay.pdfOlay.pdf
Olay.pdf
 
Costco Powerpoint Presentation
Costco Powerpoint PresentationCostco Powerpoint Presentation
Costco Powerpoint Presentation
 
UCSF Life Sciences Week 1 diagnostics
UCSF Life Sciences Week 1 diagnosticsUCSF Life Sciences Week 1 diagnostics
UCSF Life Sciences Week 1 diagnostics
 
0103 b marketing management case study report xerox 1 (1)
0103 b marketing management case study report xerox 1 (1)0103 b marketing management case study report xerox 1 (1)
0103 b marketing management case study report xerox 1 (1)
 
Medical representative day
Medical representative  dayMedical representative  day
Medical representative day
 
UCSF Life Sciences Week 2 devices
UCSF Life Sciences Week 2 devicesUCSF Life Sciences Week 2 devices
UCSF Life Sciences Week 2 devices
 
Rite Aid
Rite Aid Rite Aid
Rite Aid
 
Pfizer case study
Pfizer case studyPfizer case study
Pfizer case study
 
The Invincible Company
The Invincible CompanyThe Invincible Company
The Invincible Company
 
Valuations: What is happening and does it matter?
Valuations: What is happening and does it matter?Valuations: What is happening and does it matter?
Valuations: What is happening and does it matter?
 
Investment Thesis Fundamentals (April 2016)
Investment Thesis Fundamentals (April 2016)Investment Thesis Fundamentals (April 2016)
Investment Thesis Fundamentals (April 2016)
 
Introducing Go To Market Strategy for B2B Startups
Introducing Go To Market Strategy for B2B StartupsIntroducing Go To Market Strategy for B2B Startups
Introducing Go To Market Strategy for B2B Startups
 
Go to Market Strategy - Hemopure
Go to Market Strategy - HemopureGo to Market Strategy - Hemopure
Go to Market Strategy - Hemopure
 
Indian Pharmaceutical Industry
Indian Pharmaceutical IndustryIndian Pharmaceutical Industry
Indian Pharmaceutical Industry
 

Andere mochten auch

Haro Pharmaceutical I-Corps@NIH 121014
Haro Pharmaceutical I-Corps@NIH 121014Haro Pharmaceutical I-Corps@NIH 121014
Haro Pharmaceutical I-Corps@NIH 121014Stanford University
 
Gammaglobulin I-Corps@NIH 121014
Gammaglobulin I-Corps@NIH 121014Gammaglobulin I-Corps@NIH 121014
Gammaglobulin I-Corps@NIH 121014Stanford University
 
Steve blank moneyball and evidence-based entreprenuership
Steve blank moneyball and evidence-based entreprenuership Steve blank moneyball and evidence-based entreprenuership
Steve blank moneyball and evidence-based entreprenuership Stanford University
 
Culture Code - Resultados Digitais
 Culture Code - Resultados Digitais Culture Code - Resultados Digitais
Culture Code - Resultados DigitaisResultados Digitais
 
Lecture 1: Business Model & Customer Development
Lecture 1: Business Model & Customer DevelopmentLecture 1: Business Model & Customer Development
Lecture 1: Business Model & Customer DevelopmentStanford University
 

Andere mochten auch (20)

Clinacuity I-Corps@NIH 121014
Clinacuity I-Corps@NIH 121014Clinacuity I-Corps@NIH 121014
Clinacuity I-Corps@NIH 121014
 
Haro Pharmaceutical I-Corps@NIH 121014
Haro Pharmaceutical I-Corps@NIH 121014Haro Pharmaceutical I-Corps@NIH 121014
Haro Pharmaceutical I-Corps@NIH 121014
 
CardiaX I-Corps@NIH 121014
CardiaX I-Corps@NIH 121014CardiaX I-Corps@NIH 121014
CardiaX I-Corps@NIH 121014
 
Gammaglobulin I-Corps@NIH 121014
Gammaglobulin I-Corps@NIH 121014Gammaglobulin I-Corps@NIH 121014
Gammaglobulin I-Corps@NIH 121014
 
Innovation at 50x 031616
Innovation at 50x 031616Innovation at 50x 031616
Innovation at 50x 031616
 
Steve blank moneyball and evidence-based entreprenuership
Steve blank moneyball and evidence-based entreprenuership Steve blank moneyball and evidence-based entreprenuership
Steve blank moneyball and evidence-based entreprenuership
 
Vitruvian week 10 presentation
Vitruvian week 10 presentationVitruvian week 10 presentation
Vitruvian week 10 presentation
 
Culture Code - Resultados Digitais
 Culture Code - Resultados Digitais Culture Code - Resultados Digitais
Culture Code - Resultados Digitais
 
Lecture 1: Business Model & Customer Development
Lecture 1: Business Model & Customer DevelopmentLecture 1: Business Model & Customer Development
Lecture 1: Business Model & Customer Development
 
Knox final presentation
Knox final presentationKnox final presentation
Knox final presentation
 
Allocate Stanford 2016
Allocate Stanford 2016Allocate Stanford 2016
Allocate Stanford 2016
 
Nova Stanford 2016
Nova Stanford 2016Nova Stanford 2016
Nova Stanford 2016
 
E245 autonomow-week5
E245 autonomow-week5E245 autonomow-week5
E245 autonomow-week5
 
E245 autonomow week4
E245 autonomow week4E245 autonomow week4
E245 autonomow week4
 
Share and Tell Stanford 2016
Share and Tell Stanford 2016Share and Tell Stanford 2016
Share and Tell Stanford 2016
 
E245 autonomow week6
E245 autonomow week6E245 autonomow week6
E245 autonomow week6
 
E245 autonomow.wk2
E245 autonomow.wk2 E245 autonomow.wk2
E245 autonomow.wk2
 
E245 autonomow-week3
E245 autonomow-week3E245 autonomow-week3
E245 autonomow-week3
 
E245 autonomow week7
E245 autonomow week7E245 autonomow week7
E245 autonomow week7
 
E245 autonomow week8
E245 autonomow week8E245 autonomow week8
E245 autonomow week8
 

Ähnlich wie BCN Biosciences I-corps@nih 121014

D2M Final Presentation Submission for LinkedIn
D2M Final Presentation Submission for LinkedInD2M Final Presentation Submission for LinkedIn
D2M Final Presentation Submission for LinkedInGregory Petrossian
 
Marketplace positioning and preliminary Market forecast
Marketplace positioning and preliminary Market forecast Marketplace positioning and preliminary Market forecast
Marketplace positioning and preliminary Market forecast Gabrielle Forman
 
Advanced Medical Isotope Corp. Investor Presentation
Advanced Medical Isotope Corp. Investor PresentationAdvanced Medical Isotope Corp. Investor Presentation
Advanced Medical Isotope Corp. Investor PresentationRedChip Companies, Inc.
 
2011_10_20_slide-deck_AZ_SB6
2011_10_20_slide-deck_AZ_SB62011_10_20_slide-deck_AZ_SB6
2011_10_20_slide-deck_AZ_SB6Dr. Stefan Busch
 
Inventing, developing and commercialising targeted small-molecule drugs for p...
Inventing, developing and commercialising targeted small-molecule drugs for p...Inventing, developing and commercialising targeted small-molecule drugs for p...
Inventing, developing and commercialising targeted small-molecule drugs for p...Laura Berry
 
KCR: Cost effectiveness in clinical trials
KCR: Cost effectiveness in clinical trialsKCR: Cost effectiveness in clinical trials
KCR: Cost effectiveness in clinical trialsKCR
 
Biosimilars global congress 2014 europe copy 3 (6)
Biosimilars global congress 2014 europe  copy 3 (6)Biosimilars global congress 2014 europe  copy 3 (6)
Biosimilars global congress 2014 europe copy 3 (6)chetanpatel73
 
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Sardegna Ricerche
 
Clinical Research career
Clinical Research careerClinical Research career
Clinical Research careerAnup Kumar
 
Future supply chains for the pharmaceutical industry – a collaborative approach
Future supply chains for the pharmaceutical industry – a collaborative approachFuture supply chains for the pharmaceutical industry – a collaborative approach
Future supply chains for the pharmaceutical industry – a collaborative approachEuropean Industrial Pharmacists Group
 
Fda phacilitate2010final
Fda phacilitate2010finalFda phacilitate2010final
Fda phacilitate2010finalisoasp
 
Liquilume NSF Final Presentation
Liquilume NSF Final PresentationLiquilume NSF Final Presentation
Liquilume NSF Final PresentationStanford University
 
Advanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationAdvanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationRedChip Companies, Inc.
 
Leading Molecules to Market - An overview on licensing
 Leading Molecules to Market - An overview on licensing Leading Molecules to Market - An overview on licensing
Leading Molecules to Market - An overview on licensingBananaIP Counsels
 

Ähnlich wie BCN Biosciences I-corps@nih 121014 (20)

Cybele final presentation
Cybele final presentationCybele final presentation
Cybele final presentation
 
Sol padis dec10-llp-2013
Sol padis dec10-llp-2013Sol padis dec10-llp-2013
Sol padis dec10-llp-2013
 
D2M Final Presentation Submission for LinkedIn
D2M Final Presentation Submission for LinkedInD2M Final Presentation Submission for LinkedIn
D2M Final Presentation Submission for LinkedIn
 
Julie Corfield
Julie CorfieldJulie Corfield
Julie Corfield
 
Marketplace positioning and preliminary Market forecast
Marketplace positioning and preliminary Market forecast Marketplace positioning and preliminary Market forecast
Marketplace positioning and preliminary Market forecast
 
Advanced Medical Isotope Corp. Investor Presentation
Advanced Medical Isotope Corp. Investor PresentationAdvanced Medical Isotope Corp. Investor Presentation
Advanced Medical Isotope Corp. Investor Presentation
 
AMI Investor Presentation
AMI Investor PresentationAMI Investor Presentation
AMI Investor Presentation
 
Blog april2016 companycreation
Blog april2016 companycreationBlog april2016 companycreation
Blog april2016 companycreation
 
2011_10_20_slide-deck_AZ_SB6
2011_10_20_slide-deck_AZ_SB62011_10_20_slide-deck_AZ_SB6
2011_10_20_slide-deck_AZ_SB6
 
Inventing, developing and commercialising targeted small-molecule drugs for p...
Inventing, developing and commercialising targeted small-molecule drugs for p...Inventing, developing and commercialising targeted small-molecule drugs for p...
Inventing, developing and commercialising targeted small-molecule drugs for p...
 
KCR: Cost effectiveness in clinical trials
KCR: Cost effectiveness in clinical trialsKCR: Cost effectiveness in clinical trials
KCR: Cost effectiveness in clinical trials
 
Biosimilars global congress 2014 europe copy 3 (6)
Biosimilars global congress 2014 europe  copy 3 (6)Biosimilars global congress 2014 europe  copy 3 (6)
Biosimilars global congress 2014 europe copy 3 (6)
 
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...
Il processo di innovazione in atto: dalle strategie di brevettazione al fundr...
 
Clinical Research career
Clinical Research careerClinical Research career
Clinical Research career
 
Future supply chains for the pharmaceutical industry – a collaborative approach
Future supply chains for the pharmaceutical industry – a collaborative approachFuture supply chains for the pharmaceutical industry – a collaborative approach
Future supply chains for the pharmaceutical industry – a collaborative approach
 
Fda phacilitate2010final
Fda phacilitate2010finalFda phacilitate2010final
Fda phacilitate2010final
 
Liquilume NSF Final Presentation
Liquilume NSF Final PresentationLiquilume NSF Final Presentation
Liquilume NSF Final Presentation
 
Asclepix I-Corps@NIH 121014
Asclepix I-Corps@NIH 121014Asclepix I-Corps@NIH 121014
Asclepix I-Corps@NIH 121014
 
Advanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. PresentationAdvanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. Presentation
 
Leading Molecules to Market - An overview on licensing
 Leading Molecules to Market - An overview on licensing Leading Molecules to Market - An overview on licensing
Leading Molecules to Market - An overview on licensing
 

Mehr von Stanford University

Team Networks - 2022 Technology, Innovation & Great Power Competition
Team Networks  - 2022 Technology, Innovation & Great Power CompetitionTeam Networks  - 2022 Technology, Innovation & Great Power Competition
Team Networks - 2022 Technology, Innovation & Great Power CompetitionStanford University
 
Team LiOn Batteries - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries  - 2022 Technology, Innovation & Great Power CompetitionTeam LiOn Batteries  - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries - 2022 Technology, Innovation & Great Power CompetitionStanford University
 
Team Quantum - 2022 Technology, Innovation & Great Power Competition
Team Quantum  - 2022 Technology, Innovation & Great Power CompetitionTeam Quantum  - 2022 Technology, Innovation & Great Power Competition
Team Quantum - 2022 Technology, Innovation & Great Power CompetitionStanford University
 
Team Disinformation - 2022 Technology, Innovation & Great Power Competition
Team Disinformation  - 2022 Technology, Innovation & Great Power CompetitionTeam Disinformation  - 2022 Technology, Innovation & Great Power Competition
Team Disinformation - 2022 Technology, Innovation & Great Power CompetitionStanford University
 
Team Wargames - 2022 Technology, Innovation & Great Power Competition
Team Wargames  - 2022 Technology, Innovation & Great Power CompetitionTeam Wargames  - 2022 Technology, Innovation & Great Power Competition
Team Wargames - 2022 Technology, Innovation & Great Power CompetitionStanford University
 
Team Acquistion - 2022 Technology, Innovation & Great Power Competition
Team Acquistion  - 2022 Technology, Innovation & Great Power Competition Team Acquistion  - 2022 Technology, Innovation & Great Power Competition
Team Acquistion - 2022 Technology, Innovation & Great Power Competition Stanford University
 
Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition Stanford University
 
Altuna Engr245 2022 Lessons Learned
Altuna Engr245 2022 Lessons LearnedAltuna Engr245 2022 Lessons Learned
Altuna Engr245 2022 Lessons LearnedStanford University
 
Invisa Engr245 2022 Lessons Learned
Invisa Engr245 2022 Lessons LearnedInvisa Engr245 2022 Lessons Learned
Invisa Engr245 2022 Lessons LearnedStanford University
 
ānanda Engr245 2022 Lessons Learned
ānanda Engr245 2022 Lessons Learnedānanda Engr245 2022 Lessons Learned
ānanda Engr245 2022 Lessons LearnedStanford University
 
Gordian Knot Center Roundtable w/Depty SecDef
Gordian Knot Center Roundtable w/Depty SecDef Gordian Knot Center Roundtable w/Depty SecDef
Gordian Knot Center Roundtable w/Depty SecDef Stanford University
 
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Stanford University
 
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Stanford University
 
Team Catena - 2021 Technology, Innovation & Great Power Competition
Team Catena - 2021 Technology, Innovation & Great Power CompetitionTeam Catena - 2021 Technology, Innovation & Great Power Competition
Team Catena - 2021 Technology, Innovation & Great Power CompetitionStanford University
 
Team Apollo - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power CompetitionTeam Apollo - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power CompetitionStanford University
 
Team Drone - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power CompetitionTeam Drone - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power CompetitionStanford University
 
Team Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power CompetitionTeam Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power CompetitionStanford University
 
Team Aurora - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power CompetitionTeam Aurora - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power CompetitionStanford University
 
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...Stanford University
 
Lecture 8 - Technology, Innovation and Great Power Competition - Cyber
Lecture 8 - Technology, Innovation and Great Power Competition - CyberLecture 8 - Technology, Innovation and Great Power Competition - Cyber
Lecture 8 - Technology, Innovation and Great Power Competition - CyberStanford University
 

Mehr von Stanford University (20)

Team Networks - 2022 Technology, Innovation & Great Power Competition
Team Networks  - 2022 Technology, Innovation & Great Power CompetitionTeam Networks  - 2022 Technology, Innovation & Great Power Competition
Team Networks - 2022 Technology, Innovation & Great Power Competition
 
Team LiOn Batteries - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries  - 2022 Technology, Innovation & Great Power CompetitionTeam LiOn Batteries  - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries - 2022 Technology, Innovation & Great Power Competition
 
Team Quantum - 2022 Technology, Innovation & Great Power Competition
Team Quantum  - 2022 Technology, Innovation & Great Power CompetitionTeam Quantum  - 2022 Technology, Innovation & Great Power Competition
Team Quantum - 2022 Technology, Innovation & Great Power Competition
 
Team Disinformation - 2022 Technology, Innovation & Great Power Competition
Team Disinformation  - 2022 Technology, Innovation & Great Power CompetitionTeam Disinformation  - 2022 Technology, Innovation & Great Power Competition
Team Disinformation - 2022 Technology, Innovation & Great Power Competition
 
Team Wargames - 2022 Technology, Innovation & Great Power Competition
Team Wargames  - 2022 Technology, Innovation & Great Power CompetitionTeam Wargames  - 2022 Technology, Innovation & Great Power Competition
Team Wargames - 2022 Technology, Innovation & Great Power Competition
 
Team Acquistion - 2022 Technology, Innovation & Great Power Competition
Team Acquistion  - 2022 Technology, Innovation & Great Power Competition Team Acquistion  - 2022 Technology, Innovation & Great Power Competition
Team Acquistion - 2022 Technology, Innovation & Great Power Competition
 
Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition
 
Altuna Engr245 2022 Lessons Learned
Altuna Engr245 2022 Lessons LearnedAltuna Engr245 2022 Lessons Learned
Altuna Engr245 2022 Lessons Learned
 
Invisa Engr245 2022 Lessons Learned
Invisa Engr245 2022 Lessons LearnedInvisa Engr245 2022 Lessons Learned
Invisa Engr245 2022 Lessons Learned
 
ānanda Engr245 2022 Lessons Learned
ānanda Engr245 2022 Lessons Learnedānanda Engr245 2022 Lessons Learned
ānanda Engr245 2022 Lessons Learned
 
Gordian Knot Center Roundtable w/Depty SecDef
Gordian Knot Center Roundtable w/Depty SecDef Gordian Knot Center Roundtable w/Depty SecDef
Gordian Knot Center Roundtable w/Depty SecDef
 
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
 
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
 
Team Catena - 2021 Technology, Innovation & Great Power Competition
Team Catena - 2021 Technology, Innovation & Great Power CompetitionTeam Catena - 2021 Technology, Innovation & Great Power Competition
Team Catena - 2021 Technology, Innovation & Great Power Competition
 
Team Apollo - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power CompetitionTeam Apollo - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power Competition
 
Team Drone - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power CompetitionTeam Drone - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power Competition
 
Team Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power CompetitionTeam Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power Competition
 
Team Aurora - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power CompetitionTeam Aurora - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power Competition
 
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
 
Lecture 8 - Technology, Innovation and Great Power Competition - Cyber
Lecture 8 - Technology, Innovation and Great Power Competition - CyberLecture 8 - Technology, Innovation and Great Power Competition - Cyber
Lecture 8 - Technology, Innovation and Great Power Competition - Cyber
 

Kürzlich hochgeladen

Education and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxEducation and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxraviapr7
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational PhilosophyShuvankar Madhu
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationMJDuyan
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRATanmoy Mishra
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfYu Kanazawa / Osaka University
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.raviapr7
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptxSandy Millin
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17Celine George
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxDr. Asif Anas
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxheathfieldcps1
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfMohonDas
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17Celine George
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17Celine George
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfMohonDas
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.EnglishCEIPdeSigeiro
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxraviapr7
 

Kürzlich hochgeladen (20)

Personal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdfPersonal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
 
Education and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptxEducation and training program in the hospital APR.pptx
Education and training program in the hospital APR.pptx
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational Philosophy
 
Benefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive EducationBenefits & Challenges of Inclusive Education
Benefits & Challenges of Inclusive Education
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.
 
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
2024.03.23 What do successful readers do - Sandy Millin for PARK.pptx
 
How to Solve Singleton Error in the Odoo 17
How to Solve Singleton Error in the  Odoo 17How to Solve Singleton Error in the  Odoo 17
How to Solve Singleton Error in the Odoo 17
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptx
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptx
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdf
 
How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17How to Add a New Field in Existing Kanban View in Odoo 17
How to Add a New Field in Existing Kanban View in Odoo 17
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdf
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptx
 

BCN Biosciences I-corps@nih 121014

  • 1. BCN Biosciences Team - Andrew Norris (PI), Mai Brooks (IE), Sudip Chakrabortty (CL) Validating Business Model for – Drug that increases anti-cancer effect of radiation in lung cancer (and/or reduces normal tissue damage by at least 40% compared to standard of care) Team 07 I-Corps @ NIH – Dec 09, 2014 Interviews total= 101 Avg/wk = 10
  • 2. What we thought going into of ICorps 2 1 indication – Radiation Mitigation Radiation Oncologists the main customer segment Some MOA data is important Phase1 Clinical Trials data required to license out the molecule We need to raise $5M+ to take the technology forward and it would take 6 years
  • 3. The ICorps Journey – Customer Discovery 3
  • 5. Right Side Canvas Week 1 Indication Customer segment Value Proposition Minimal Viable Product Investment Readiness Normal Tissue Protection from Radiation Radiation & Clinical Oncologists Protects lung / normal tissue from radiation Lung fibrosis and pneumonitis •8 5
  • 6. Left Side Canvas Week 3 Value Prop Key Activities Key Partners Minimal Viable Product Normal tissue protection Show tissue protection in various animal models. Limit Lung fibrosis and pneumonitis Academic •Animal models showing normal tissue protection. 6
  • 7. What we did - Archetypes of Customer & Partners Doctors Pharma Biz Dev Pharma Prod Dev / Science Development Partners Archetype Pulmonologists -patients with post radiation fibrosis -patients with IPF Skin Doctors -Dermatologists -Plastic Surgeons Big Pharma/Biotech -Pitched hundreds of times each year -Looking for $1B market molecules -Disease modifying Medium Pharma/Biotech -Actively engaged in pre- clinical scouting -Interested in supportive care also Big & Medium Pharma/ Biotech -Conducts pre-clinical MOA studies -Conducts Efficacy & Safety studies -Designs in-human clinical trials and regulatory path -Primary Science/ Regulatory/manuf decision influencers CROs -Radiation CROs -PK, Tox & Efficacy CROs -Drug Formulations -Drug manufacturing Govt. Agencies -Development partner -Free resources Disease Foundations -Basic Research support mandate -Orphan Indications Interviewees 26 34 18 22 7
  • 8. 8 The BCN Strategy evolution at ICorps@NIH Week 1 Week 6 Week 10 Radiation Mitigator & Tumor Sensitizer Prevents Radiation Induced Lung Fibrosis 1 8
  • 9. 9 The BCN Strategy evolution at ICorps@NIH Week 1 Week 6 Week 10 Radiation Tumor Sensitizer Prevents Radiation Induced Lung Fibrosis Fibrosis Possible MOA – Stem Cell Big Market size for fibrosis – unmet need 1 9
  • 10. 10 The BCN Strategy evolution at ICorps@NIH Week 1 Week 6 Week 10 Radiation Mitigator & Tumor Sensitizer Prevents Radiation Induced Lung Fibrosis Fibrosis Possible MOA – Stem Cell Lung Fibrosis (IPF*) Skin Fibrosis (Anti aging) Other Fibrosis types Big Market size for fibrosis – unmet need 1 2 3 * Idiopathic Pulmonary Fibrosis 10
  • 11. Week 7 Canvas 6 Hypothesis Validated, >15 invalidated 11
  • 12. Week 10 Canvas 16 Hypothesis Validated, 10+ validation still in progress 12
  • 13. Right Side Canvas Week 10 Value Prop Customer segment Value Proposition Minimal Viable Product Investment Readiness Tumor Sensitizer Radiation Oncologists In-License/BD Increase survival >3 months vs. SOC •Reduces tumor burden vs Radiation. •MOA •5-6 IPF Pulmonologists In-License/BD Reduce pulmonary fibrosis > SOC •2 more animal models for IPF •MOA •2-3 Anti-aging Dermatologists Reduces age related markers •Mini pig skin injury model. •Human test- reduce collagen over 6 months •2 13
  • 14. Market Size – TAM, SAM, Target Yearly Cancer Incidences = 5.1M Lung = 630K Radiation Therapy = 410K Mortality = 160K Radiation Complications = 64K TAM = $6B SAM = $2B Target Market = $1B Indication – Radiation Sensitizer for Lung Cancer Tumors 14
  • 15. Left Side Canvas Week 10 Value Prop Key Activities Key Partners Minimal Viable Product Tumor Sensitizer MVP = •MOA, •Animal (reduces tumor burden vs radiation alone). • (TPP) Tumor sensitizer that increases life by at least 3 months in conjunction with SOC. Cleveland Bio UCLA, •Sensitizes tumor tissue to radiation vs radiation alone. •Lung fibrosis and pneumonitis IPF MVP = MOA!!, two other models that show better efficacy than standard of care, work with ……*(Companies Names) Lovelace •MOA •2 more animal models for IPF Anti-aging MVP (strong prelim data showing reduction in collagen production in mouse model and human skin (over 6 months). CitoxLab North America. •Mini pig skin injury model. •Human test-reduce collagen over 6 months 15
  • 16. Companies & KOL Possible Customers Competi- tors KOL Dr. Andre Gudkov Dr. Robert Figlin Dr. Luca Richeldi Dr. Talmadge King Dr. Richard Fitzpatrick Radiation sensitizer, target companies that sell lung cancer drugs IPF, target companies that sell drugs for lung disease Anti-aging cream, target companies that sell skin products 1 2 3 16
  • 17. Customer Relationship-Commitment Diagram 17 BCN Bio BCN Biz Dev Sci Ad Board Months 0 1 6 12 18 Network Scientific meetings & trade shows Grants, pubs License, venture deal Design & do clinical trial GET GROW Pharma licensing Decision Makers Pharma Venture Venture Capital Doctors Customers KEEP
  • 18. Partners – Preclinical /Phase 1 Clinical Partner Type Partner Name Why Partner & What Risk Why BCN & Costs Incentives CML & AAI Pharma – Formulation & Drug product - Industry standard & GMP - No in-house facilities @ BCN Risk - Partner Project Management - CRO business model - New areas to show expertise & publish (radiation & IPF) Costs ~ $600K (pre-clin) - Revenue Model - New Business possibilities CiToxLAB/SNBL – Radiation & Cancer Efficacy & Safety Lovelace – Pulmonary Indication Efficacy & Safety - Industry Standard & GLP - No in-house facilities Risk – Partner Project Management & IP share on any new animal model - CRO business model - New areas to show expertise & publish (radiation & IPF - Potential shared IP on animal model Costs ~ $1.1M (pre-clin) - Revenue Model - Potential IP - New Business possibilities UCLA Expertise in Radiation Sensitizer Animal Model & related MOA - BCN team has significant Pharma expertise in the relevant fields - Not many pharma or biotech working on this filed Unique ability to bring Academia, Govt. & Industry together Costs ~ $500K (sponsored research) - In the Academic institutions best interest to help commercialize IP originally funded by grants - Publications - Extra funding in form of sponsored Research Albert Einstein College of Medicine Expertise in Head & Neck animal model (Mucositis) University of Maryland (probable) Expertise in Pulmonary Fibrosis Animal model & related MOA Risk – Potential IP issues CRO Academia 18
  • 19. Partners – Preclinical /Phase 1 Clinical Partner Type Partner Name Why Partner & What Risk Why BCN & Costs Incentives CML & AAI Pharma – Formulation & Drug product - Industry standard & GMP - No in-house facilities @ BCN Risk - Partner Project Management - CRO business model - New areas to show expertise & publish (radiation & IPF) Costs ~ $600K (pre-clin) - Revenue Model - New Business possibilities CiToxLAB/SNBL – Radiation & Cancer Efficacy & Safety Lovelace – Pulmonary Indication Efficacy & Safety - Industry Standard & GLP - No in-house facilities Risk – Partner Project Management & IP share on any new animal model - CRO business model - New areas to show expertise & publish (radiation & IPF - Potential shared IP on animal model Costs ~ $1.1M (pre-clin) - Revenue Model - Potential IP - New Business possibilities UCLA Expertise in Radiation Sensitizer Animal Model & related MOA - BCN team has significant Pharma expertise in the relevant fields - Not many pharma or biotech working on this filed Unique ability to bring Academia, Govt. & Industry together Costs ~ $500K (sponsored research) - In the Academic institutions best interest to help commercialize IP originally funded by grants - Publications - Extra funding in form of sponsored Research Albert Einstein College of Medicine Expertise in Head & Neck animal model (Mucositis) University of Maryland (probable) Expertise in Pulmonary Fibrosis Animal model & related MOA Risk – Potential IP issues CRO Academia 19 There are Risks in Partnerships also - we need to be aware
  • 20. Partners – Preclinical /Phase 1 Clinical Partner Type Partner Name Why Partner & What Risk Why BCN & Costs Incentives NCI SBIR & Next program - For Radiation & Cancer NHLBI SBIR and other program – For IPF indication - Phase 1 & Phase 2 funding - Access to World Class facilities for free Risk - Risk of not getting selected, so need plan B - One of the promising your SB biotech working on other indications for Radiation Mitigators -Govt. mandate Costs – No costs to BCN - Stimulating economy through fundamental research NIAID & BARDA - NIAID funding covers most IND enabling studies - BARDA Contracts can be utilized for Clinical trials using Animal Rule Risk – Risk of not getting selected, Tech Readiness Level 5 required - BARDA especially looking for molecules with other in-human indications Costs – No costs to BCN - Public Safety -Maximum return on tax payer dollars Pharma & Biotech interested in Radiation Sensitizer & Cancer indications -Perform MOA studies pre- IND (research) -Scale up GMP formulation & drug product pre-IND -Experts in IP protection -Expertise in Clinical Trials & Regulatory -Sales & Marketing Channels -License out within 3 years Risk – They might kill the project - BCN team has pre- eminent Prod Dev expertise in the relevant fields - Orphan Indication (IPF) -Smart use of partnerships Costs – Giving up control and big future Revenue Potential - Potential Radiation Sensitizer & Head & Neck cancer indication market big - Picking up a multi-indication molecule for cheap Pharma & Biotech interested in Pulmonary Fibrosis Govt. Agencies Pharma & Biotech 20
  • 21. Partners – Preclinical /Phase 1 Clinical Partner Type Partner Name Why Partner & What Risk Why BCN & Costs Incentives NCI SBIR & Next program - For Radiation & Cancer NHLBI SBIR and other program – For IPF indication - Phase 1 & Phase 2 funding - Access to World Class facilities for free Risk - Risk of not getting selected, so need plan B - One of the promising your SB biotech working on other indications for Radiation Mitigators -Govt. mandate Costs – No costs to BCN - Stimulating economy through fundamental research NIAID & BARDA - NIAID funding covers most IND enabling studies - BARDA Contracts can be utilized for Clinical trials using Animal Rule Risk – Risk of not getting selected, Tech Readiness Level 5 required - BARDA especially looking for molecules with other in-human indications Costs – No costs to BCN - Public Safety -Maximum return on tax payer dollars Pharma & Biotech interested in Radiation Sensitizer & Cancer indications -Perform MOA studies pre- IND (research) -Scale up GMP formulation & drug product pre-IND -Experts in IP protection -Expertise in Clinical Trials & Regulatory -Sales & Marketing Channels -License out within 3 years Risk – They might kill the project - BCN team has pre- eminent Prod Dev expertise in the relevant fields - Orphan Indication (IPF) -Smart use of partnerships Costs – Giving up control and big future Revenue Potential - Potential Radiation Sensitizer & Head & Neck cancer indication market big - Picking up a multi-indication molecule for cheap Pharma & Biotech interested in Pulmonary Fibrosis Govt. Agencies Pharma & Biotech 21 Partnership is a 2 way street – Partners expect specific things from BCN too
  • 22. What we thought going into of ICorps 22 1 indication – Radiation Mitigation Radiation Oncologists the main customer segment Some MOA data is important Phase1 Clinical Trials data required to license out the molecule We need to raise $5M+ to take the technology forward and it would take 6 years
  • 23. So what did we really learn in 10 weeks at ICorps 23 1 indication – Radiation Mitigation Radiation Oncologists the main customer segment Some MOA data is important Phase1 Clinical Trials data required to license out the molecule We need to raise $5M+ to take the technology forward and it would take 6 years 3 possible indications – & Tumor Sensitization; IPF, Skin Pharma company in-licensing Directors most important customer segment MOA data is required for 2 of the 3 indications Its possible to license out or partner at a pre-IND stage We can do this in <$2M and in <3 years
  • 24. BCN Biosciences – Next Steps •With respect to submitting an SBIR/STTR Phase II application, we will write on our primary indication of radiation sensitizer/protector in lung cancer. •The feasibility data generated in the Phase I grant provide the appropriate technical foundation for a Phase II application, AND we are largely targeting the customer segments that we had originally anticipated •TRL level 6 24
  • 25. Timeline Stage Activities Partners Key Markers Timeline Pre-Clinical Phase 1 Phase 2 Phase 3 IND Data Package Pharma Data Package Safety Initial MOA Efficacy Academia CRO Govt CRO BCN Biosciences Pharma Partner/s $ $ $ $ $ $ $ $ $ $ $ $ $ $ D F A $ B C G 6 months 6 months 18 months 1 year 2 years 4 years 10 years A B C D E F C License Molecule from Academia Sponsored Research @ Academia Govt. Grant/Cooperative Agmt/Contract Partnership Agreement with Pharma License molecule out to Pharma E.g. Milestone Payments to BCN Royalty Payments to BCN 25 IND E F FDA Approval Definitive MOA Studies Clinical Trials Animal Model Dev CMC Sales & Marketing